<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297683</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003518</org_study_id>
    <nct_id>NCT04297683</nct_id>
  </id_info>
  <brief_title>HEALEY ALS Platform Trial - Master Protocol</brief_title>
  <official_title>HEALEY ALS Platform Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit E. Cudkowicz, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
      evaluating the safety and efficacy of investigational products for the treatment of ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
      evaluating the safety and efficacy of investigational products for the treatment of ALS. This
      trial is designed as a perpetual platform trial. This means that there is a single Master
      Protocol dictating the conduct of the trial.

      In this trial, multiple investigational products for ALS will be tested simultaneously or
      sequentially. Each investigational product will be tested in a regimen. Each regimen consists
      of a placebo-controlled trial, meaning that the active investigational product and matching
      placebo will be tested in each regimen.

      The additional details that govern the testing of each investigational product will be
      summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate
      ClinicalTrials.gov posting, which will include specific information about the regimen. All
      regimen-specific outcome measures will be detailed in each regimen posting.

      Participants will have an equal chance to be randomized to all regimens that are active at
      the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1
      ratio to either study drug or placebo.

      The following regimens are active in the trial:

      Regimen A - Zilucoplan Regimen B - Verdiperstat Regimen C - CNM-Au8

      New regimens will be continuously added as new investigational products become available. The
      HEALEY ALS Platform Trial will enroll additional participants as each new regimen is
      available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>As new investigational products become available, additional regimens will be added to the HEALEY ALS Platform Trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Function</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in respiratory function over time as measured by Slow Vital Capacity (SVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Comparison of rate of occurrence between groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Regimen A - Zilucoplan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active zilucoplan or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B - Verdiperstat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active verdiperstat or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C - CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active CNM-Au8 or matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilucoplan</intervention_name>
    <description>Drug: Zilucoplan
Administration: Subcutaneous injection
Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight</description>
    <arm_group_label>Regimen A - Zilucoplan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verdiperstat</intervention_name>
    <description>Drug: Verdiperstat
Administration: Oral
Dose: 600mg twice daily</description>
    <arm_group_label>Regimen B - Verdiperstat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNM-Au8</intervention_name>
    <description>Drug: CNM-Au8
Administration: Oral
Dose: 30 mg or 60 mg daily</description>
    <arm_group_label>Regimen C - CNM-Au8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported
             probable, or definite ALS defined by revised El Escorial criteria.

          2. Age 18 years or older.

          3. Capable of providing informed consent and complying with study procedures, in the SI's
             opinion.

          4. Time since onset of weakness due to ALS ≤ 36 months at the time of the Master Protocol
             Screening Visit.

          5. Vital Capacity ≥ 50% of predicted capacity for age, height, and sex at the time of the
             Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required
             due to pandemic-related restrictions, Forced Vital Capacity (FVC).

          6. Participants must either not take riluzole or be on a stable dose of riluzole for ≥ 30
             days prior to the Master Protocol Screening Visit. Riluzole-naïve participants are
             permitted in the study.

          7. Participants must either not take edaravone or have completed at least one cycle of
             edaravone prior to the Master Protocol Screening Visit. Edaravone-naïve participants
             are permitted in the study.

          8. Participants must have the ability to swallow pills and liquids at the time of the
             Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow
             for the duration of the study.

          9. Geographically accessible to the site.

        Exclusion Criteria:

          1. Clinically significant unstable medical condition (other than ALS) that would pose a
             risk to the participant, according to SI's judgment (e.g., cardiovascular instability,
             systemic infection, untreated thyroid dysfunction, or clinically significant
             laboratory abnormality or EKG changes).

             Lab abnormalities include, but are not limited to: Hemoglobin &lt; 10 g/dL, White Blood
             Cells &lt; 3.0 x 103/mm3, Neutrophils, Absolute ≤ 1000/mm3, Eosinophilia (absolute
             eosinophil count of ≥ 500 eosinophils per microliter), low platelet counts (&lt; 150 x
             109 per liter), alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
             greater than 3 times the upper limit of normal (ULN), eGFR &lt; 30 mL/min/1.73m2,
             thyroid-stimulating hormone (TSH) levels &gt;10 mIU/L or &lt;0.01 mIU/L.

          2. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance
             abuse that would impair ability of the participant to provide informed consent, in the
             SI's opinion.

          3. Active cancer or history of cancer, except for the following: basal cell carcinoma or
             successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ,
             prostatic carcinoma in situ, or other malignancies curatively treated and with no
             evidence of disease recurrence for at least 3 years.

          4. Use of investigational treatments for ALS (off-label use or active participation in a
             clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior
             to the Master Protocol Screening Visit.

          5. Exposure at any time to any gene therapies under investigation for the treatment of
             ALS (off-label use or investigational).

          6. If female, breastfeeding, known to be pregnant, planning to become pregnant during the
             study, or of child-bearing potential and unwilling to use effective contraception for
             the duration of the trial and for 3 months, or longer as specified in each RSA, after
             discontinuing study treatment.

          7. If male of reproductive capacity, unwilling to use effective contraception for the
             duration of the trial and for 3 months, or longer as specified in each RSA, after
             discontinuing study treatment.

          8. Anything that would place the participant at increased risk or preclude the
             participant's full compliance with or completion of the study, in the SI's opinion.

          9. If a participant is being re-screened, the disqualifying condition has not been
             resolved, or the mandatory wash-out duration has not occurred.

         10. For those participating in the optional CSF collection, contraindication to undergoing
             a lumbar puncture (LP) in the SI's opinion. Participants undergoing the LP must not be
             currently taking anticoagulation medications such as warfarin that would be a
             contraindication to LP; aspirin and non-steroidal anti-inflammatories are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HEALEY Center for ALS at Massachusetts General Hospital</last_name>
    <phone>833-425-8257 (HALT ALS)</phone>
    <email>healeyalsplatform@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessie Duncan</last_name>
      <email>Jessie.Duncan@DignityHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Blanca Herrera</last_name>
      <email>bherrera@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolyn Prina</last_name>
      <email>carolyn.prina@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivian Li</last_name>
      <email>vcli1@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Forbes Norris MDA/ALS Research Center, California Pacific Medical Cente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marguerite Engel</last_name>
      <email>engelm@cpmcri.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brianna Blume</last_name>
      <email>Brianna.Blume@CUAnschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie Schmitt</last_name>
      <email>nschmitt@hfsc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phil Smith Neuroscience Institute at Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donovan Mott</last_name>
      <email>donovan.mott@holy-cross.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Steshyn</last_name>
      <email>jennifer.steshyn@neurology.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Thuro</last_name>
      <email>thuro.lisa@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Levy</last_name>
      <phone>888-413-9315</phone>
      <email>alsresearch@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Shaw</last_name>
      <email>jessshaw@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meraida Polak</last_name>
      <email>mpolak@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben Joslin</last_name>
      <email>ben.joslin@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shail Bhatnagar</last_name>
      <email>sbhatnagar@neurology.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeri Sieren</last_name>
      <email>jeri-sieren@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Heim</last_name>
      <email>AHeim2@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meg Bruno</last_name>
      <email>meghann.bruno@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Brown</last_name>
      <email>kristina.brown@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vikram Nambiar</last_name>
      <email>vnambiar@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristen Riley</last_name>
      <email>kriley15@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Hevert</last_name>
      <phone>617-643-3902</phone>
      <email>MGHsiteHealeyPlatform@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hilda Guitierrez</last_name>
      <email>hgutier1@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>North Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane McKenna-Yasek</last_name>
      <email>Diane.McKenna-Yasek@umassmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jayna Duell</last_name>
      <email>jkballar@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Vallis</last_name>
      <email>avallis1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nichole Roderique</last_name>
      <email>nichole.roderique@spectrumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Twin Cities ALS Research Consortium</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hilda Guitierrez</last_name>
      <email>hgutier1@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Denny</last_name>
      <email>denny.carol@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie Taylor</last_name>
      <email>taylornat@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Brown</last_name>
      <email>susan.a.brown@health.slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Karanja</last_name>
      <email>ekaranja@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.C./Somnos Clinical Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Desirae Eschiti</last_name>
      <email>Desi@somnos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renee Hogue</last_name>
      <email>rhogue@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caren Saunders</last_name>
      <email>Caren.H.Saunders@hitchcock.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brixhilda Dedi</last_name>
      <email>bd2577@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Pusey</last_name>
      <email>PuseyJ@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Harrison</last_name>
      <email>Lisa.harrison@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health Science</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mozhdeh Marandi</last_name>
      <email>mmarandi@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Cohen</last_name>
      <email>erin.cohen@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arlena Cummings</last_name>
      <email>arlena.cummings@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Haulman</last_name>
      <email>ahaulman@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jefferson Weinberg ALS Center, Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Oakley</last_name>
      <email>laura.oakley@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Penn</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adreeja Guharay</last_name>
      <email>Adreeja.Guharay@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lewis Katz School of Medicine at Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Hatala</last_name>
      <email>kathleen.hatala@tuhs.temple.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katrina Madden</last_name>
      <email>maddenka@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Benzel</last_name>
      <email>cbenzel@wesleyneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Davis</last_name>
      <email>diana.davis@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Morgan</last_name>
      <email>tmorgan@texasneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Applegate</last_name>
      <email>rgapplegate@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Mendoza</last_name>
      <email>pamendoza@houstonmethodist.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Kittrell</last_name>
      <email>kittrellp@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Wagoner</last_name>
      <email>MIW9B@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Sissons-Ross</last_name>
      <email>lsissons@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Mejaki</last_name>
      <email>mmejaki@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Merit E. Cudkowicz, MD</investigator_full_name>
    <investigator_title>Chief, Neurology Department</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Master Protocol</keyword>
  <keyword>Lou Gehrig's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

